Molecular Genetics Studies of Cancer Patients and Their Relatives
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04185935|
Recruitment Status : Recruiting
First Posted : December 4, 2019
Last Update Posted : September 16, 2021
|Condition or disease||Intervention/treatment|
|Malignant Neoplasm||Other: Biospecimen Collection Other: Questionnaire Administration|
I. To identify rare cancer patients and families in whom the pattern of disease suggests a genetic susceptibility to cancer or other etiology suggestive of a carcinogenic exposure and to characterize the underlying predisposition.
II. To determine the contribution of heredity (genotype) and biomarkers to clinical outcome (phenotype, occurrence of new cancers, prognosis and quality of life) in subgroups of cancer patients with and without clinical high-risk features.
Patients may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
|Study Type :||Observational|
|Estimated Enrollment :||999999 participants|
|Official Title:||Molecular Genetics Studies of Cancer Patients and Their Relatives|
|Actual Study Start Date :||April 18, 1997|
|Estimated Primary Completion Date :||May 5, 2030|
|Estimated Study Completion Date :||May 5, 2030|
Ancillary-correlative (biospecimen collection)
Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
Other: Biospecimen Collection
Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
Other: Questionnaire Administration
- Cancer risk assessment [ Time Frame: Up to 10 years ]
- Exploratory biomarkers for future studies [ Time Frame: Up to 10 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04185935
|Principal Investigator:||Jeffrey N Weitzel||City of Hope Medical Center|